Replies to post #827 on Venaxis Inc fka APPY

[bioresearcher]

A "small" but very important point:

"We are also fortunate to receive additional regulatory guidance from FDA for the study, which modified the trial design, specifically the way candidate patients are identified and recruited into the study, making it slightly more stringent to make sure we're evaluating the right patients. Managing these additional factors took a little extra time. We are now seeing enrollment trends improving. We feel confident in our updated estimate for the timing of trial completion by year end."

*from the cc